PARLIAMENTARY WRITTEN QUESTION
Coronavirus: Vaccination (5 July 2021)

To ask the Secretary of State for Health and Social Care, what guidance his Department provides to Novavax covid-19 vaccine trial participants who have been unblinded and received two vaccine doses under that trial over six months ago on whether they should receive an approved covid-19 vaccination.

Asked by:
Navendu Mishra (Labour)

Guidance has been provided to support vaccine trial participants who wished to be unblinded at a time when they became eligible for an approved COVID-19 vaccine. This suggests individuals should discuss with the principle investigator at the site in which the participant was recruited who are best placed to advise on the options following unblinding.

In general, participants who only received a placebo would be recommended to receive the deployed COVID-19 vaccine schedule. Those that received a full course of an active vaccine, would be advised that further doses of deployed vaccine were not advisable. Whilst antibody tests were performed in the study, the advice on further vaccination would be based on the record of the participant's previous doses in the trial.

Answered by:
Nadhim Zahawi (Conservative)
13 July 2021